The Global Autoimmune Disease Partnering 2010-2015 report provides comprehensive understanding and unprecedented access to the autoimmune partnering deals and agreements entered into by the worlds leading healthcare companies

Recent market research analysis by Current Agreements shows that partnering in the last decade has seen an increase in cardiovascular deals with an increase in modern diagnostic technology development.

By Shamini Thiagarajan Increased collaborations, big pharma involvements, venture capital investments, and medical/technological breakthroughs are together changing the landscape of research and development in orphan diseases.

Current Partnering releases its first update of the article previously published last year on the most partnered therapeutic trends in pharma. The article analyses the most partnered therapeutic targets of 2009-2014 and identifies the areas that have gained in popularity since last year and the new areas that have entered the list

Partnering in the last decade has seen an increase in dermatology with an rise specifically in modern diagnostic technologies.

Partnering in the last decade has seen an increase in oncology partnering with an increase in modern diagnostic technologies, according to recent partnering deals analysis

Recent trends analysis suggests that research in personalized medicine and vaccine development for disease treatment has increased partnering and collaboration in this arena. 

Deal analysis by Current Agreements  shows that ophthalmics dealmaking activity has been steady with an average of 68 deals signed since 2009.

An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.

Scientists predict that the cure to cancer in the future lies in exploiting personalized medicine technology.